Abstract
Background: Large scale studies of outcomes of Gonadotropin-releasing hormone analogue (GnRHa) therapy for Central Precocious puberty (CPP) are not available from our part of the country.Aim: To evaluate the efficacy of GnRHa with clinical and biochemical parameters in a cohort of children with CPP.Methodology: Retrospective analysis of case records of 33children (30 females and 3 males) diagnosed with CPP on GnRHa (Leuprolide acetate depot) was done.Results: CPP was idiopathic in 20 and organic in 13 children. Median age at onset of puberty was 6.75years (range 0.75 – 8.9 years) and at start of treatment was 7years. The Median duration of therapy was 2.75years (range= 5months-9years). 52% attained LH Suppression in one year and 81% in two years. 92% patients had regression in tanner's stage by a median of 11months. BA was advanced by a median of 4.45 SD which reduced to 2.8SD at the end of therapy. Duration of therapy had significant effect in halting BA progression (p=0.004). The median height centile of 86.25 at presentation normalised in 89% at treatment completion.Conclusion: GnRHa therapy in our cohort of CPP children was effective in reversing puberty and slowing bone age advancement despite a late age of onset of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
